This article was reported by AIDSmeds.
AIDSmeds reported that an essay in the Lancet points to an increase in the use of the pre-exposure prophylaxis (PrEP) Truvada (tenofovir/emtricitabine) to prevent HIV-negative people from acquiring the infection. The essay reports that only 1,774 people used the drug between January 2011 and March 2013; however, healthcare providers issued 20 percent of new prescriptions in the first three months of 2013, which indicates an upsurge in people seeking to use it.
Due to questions, concerns, and controversies about the application of the drug, several clinical trials are researching toxicity and non-adherence of Truvada as PrEP. However, it is still believed that many of those enrolled in the studies will want to continue with the drug after the trials have ended.
Other studies are researching the effectiveness of Truvada at less-than-daily dosage, as well as studying whether men who have sex with men (MSM) are increasing their high-risk activities due to a perception that using a PrEP will protect them from acquiring HIV.
The full report, "Uptake of PrEP for HIV Slow Among MSM," was published in the journal the Lancet (2014; 383 (9915): 399-400).
Back to other news for February 2014
This article was provided by CDC National Prevention Information Network.
It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy